Please wait while we load the requested 10-K report or click the link below:
FOR IMMEDIATE RELEASE
CONFERENCE CALL DETAILS ON PAGE TWO
AEGERION PHARMACEUTICALS ANNOUNCES
FOURTH-QUARTER AND FULL-YEAR 2011 FINANCIAL RESULTS
Company Submits Marketing Applications for Lomitapide in US and EU
Cambridge, MA, March 6, 2012 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced its financial results and business highlights for the fourth-quarter and year ended December 31, 2011. Aegerion recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of Aegerions lead investigational therapeutic, lomitapide, as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in patients with Homozygous Familial Hypercholesterolemia (HoFH). Late in the day on March 5, 2012, the FDA informed Aegerion that the NDA filing would receive standard review.
We closed 2011 having made significant progress to ready ourselves for a potential commercial launch of lomitapide, said Marc D. Beer, Chief Executive Officer. Following our recent regulatory submissions, we have now turned our attention to working with the HoFH community to identify patients, educate on the disease and increase awareness. We entered 2012 with great momentum, having established a team highly experienced in the rare disease area. This team continues to be motivated by the potential to bring an important therapy to patients who currently have inadequate treatment options available.
Fourth-Quarter and Year-End 2011 Corporate Highlights
In October 2011, Aegerion completed its Phase III clinical trial of lomitapide in adult patients with Homozygous Familial Hypercholesterolemia, and in January 2012, Aegerion announced that the 78-week results from the trial were consistent with data previously reported at the 26-and 56-week time points.
The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Tuesday, March 6, 2012 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Aegerion Pharmaceuticals, Inc..